The efficacy of photodynamic therapy (PDT) for epithelial cancers is increased when PDT is combined with calcitriol (Vit D), a form of differentiation therapy (DT). Here, we describe an underlying mechanism for this effect. Differentiation-promoting agents are known to upregulate CCAAT/enhancer-binding proteins (C/ EBP), powerful regulators of cellular differentiation. In subcutaneous A431 tumors in mice, pretreatment with Vit D induced the expression of C/EBPb isoforms, and of coproporphyrinogen oxidase (CPO), a heme pathway enzyme responsible for the conversion of 5-aminolevulinic acid (ALA) into protoporphyrin IX (PpIX), the principal light-absorbing molecule during PDT. To further investigate this apparent link between C/EBPs and CPO, two cell lines (MEL and LNCaP) were exposed to differentiating agents, and levels of PpIX, C/EBPs, and CPO were measured. Differentiating agents, or transfection of C/EBP expression vectors, increased C/EBP and CPO levels in parallel. Focusing on approximately 1,300 bp of upstream CPO gene promoter, we tested the ability of recombinant C/EBPa, C/EBPb, C/EBPd, and C/EBPz to bind to CPO gene sequences [electrophoretic mobility shift assay (EMSA) assays] and to affect transcriptional activity (luciferase assays). Multiple C/EBP consensus binding sites were identified (15 for mouse, 18 for human). Individual probes representing each site bound to C/EBPs with characteristic affinities (strong, moderate, or weak), but when sites were inactivated in the context of the native promoter, transcriptional activity was reduced nearly equally for strong or weak sites. Cooperative interactions between regularly spaced C/EBP sites seem critical for CPO transcriptional regulation by differentiation therapy. These results provide a mechanistic rationale for DT/ PDT combination therapy for cancer. Mol Cancer Ther; 12(8); 1638-50. Ó2013 AACR.
Introduction
Photodynamic therapy (PDT) is a relatively new anticancer technique in which a photolabile molecule is allowed to selectively accumulate in cancer cells, followed by illumination with high-intensity light to activate the photosensitizer and kill the cells (1, 2) . One particularly useful approach is to administer 5-aminolevulinic acid (ALA), a prodrug selectively taken up by cancer cells and metabolically converted into intracellular porphyrins (3) . Porphyrins, mainly protoporphyrin IX (PpIX), are efficient absorbers of visible light. In the presence of oxygen, PpIX is photochemically degraded and forms free radical species that damage membranes and trigger apoptosis (3).
PpIX is synthesized from ALA by the sequential action of 8 enzymes in the heme-synthetic pathway (4), including coproporphyrinogen oxidase (CPO, sixth enzyme in the cascade). CPO lies upstream of PpIX, and is of particular interest because CPO is rate-limiting for PpIX production under typical PDT conditions (5) .
To try to further improve the treatment efficacy of PDT, we have empirically pretreated cells and tumors with various agents before ALA-PDT, and found several pretreatments that cause significant elevations of intracellular PpIX levels (6) . To date, the following agents have been shown to improve both PpIX accumulation and the therapeutic response: (i) skin or prostate carcinoma cells pretreated with methotrexate (5, 7, 8) ; (ii) various carcinomas pretreated with vitamin D3 (9, 10); (iii) hormone-responsive prostate cancer cells pretreated with androgens (7); and (iv) skin keratinocytes pretreated with calcium (8, 10, 11) . In all cases, the pharmacologic pretreatment promoted CPO expression, PpIX levels, and cellular differentiation concurrently (8, 10, 11) . We are interested in identifying the mechanisms behind these effects. A positive correlation between agents that induce cellular differentiation and PpIX levels might be only coincidental, unless an underlying mechanism can be proposed and shown.
Consideration of the literature about differentiation therapy (DT), defined as the use of biologic agents to promote cancer cell maturation, offered a clue here. The use of retinoids to drive terminal differentiation of promyelocytic leukemia cells is a familiar example of differentiation therapy (12, 13) ; another is the use of interleukin (IL)-15 to eliminate renal cancer stem cells (14) . Mechanisms for differentiation therapy are thought to involve nuclear transcription factors that regulate genes governing proliferation and differentiation. CCAAT/enhancerbinding proteins (C/EBPs) are top candidates for this role. C/EBPs were among the first transcription factors identified as powerful regulators of differentiation programs in adipocytes (15, 16) , hepatocytes (17, 18) , blood cell lineages (19) , and keratinocytes (20, 21) . More recently, dysregulated expression of C/EBPa and C/EBPb was shown to be important in the pathogenesis of myeloid, lung, breast, and skin cancers (12, 13, 19, (22) (23) (24) . Relevant to our work is the fact that many C/EBP family members are implicated in driving cellular differentiation in response to pharmacologic agents such as calcium (25) , methotrexate (26) , or vitamin D (27) . With this background, we asked whether C/EBP factors might be involved in driving transcription of the CPO gene during combination DT/PDT. Here, we describe a molecular investigation in which C/EBPs are shown to regulate CPO gene expression in cancer cells from 2 species, mouse and human. The evidence strongly suggests that C/EBPs are important regulators of CPO expression and PpIX photosensitizer accumulation, thereby defining an underlying mechanism for DT/PDT combination therapy.
Materials and Methods
Subcutaneous A431 tumors in mice, pretreatment with vitamin D, and measurement of PpIX and various proteins in tissue Nude mice (female, 6 weeks; Charles River Laboratory) were injected with 2 Â 10 6 A431 cells in the flanks. Mice with visible/palpable tumors (6-10 days postinjection) were preconditioned with systemic vitamin D (5 mg/kg) in PBS or PBS alone (vehicle control) daily for 3 days by an intraperitoneal (i.p.) route. ALA (200 mg/kg) was administered for 4 hours i.p. Tumors were harvested, and PpIX measured in frozen sections by confocal microscopy as described previously (10) . Protein expression was analyzed by immunofluorescent staining or by Western blotting as described previously (10) .
Cell culture
MEL erythroleukemia cells, LNCaP prostate carcinoma cells, A431, and COS-7 cells were obtained from American Type Culture Collection (ATCC), and cultured as recommended by the supplier. Cell lines were tested and authenticated at ATCC by morphologic appearance during growth and recovery, cytochrome C oxidase 1 PCR for species specificity, and human origin by short-tandem repeat (STR) profiling.
Pretreatment of MEL cells with DMSO and measurement of PpIX in cell lysates
Murine erythroleukemia line (MEL) cells in 25 cm 2 flasks were incubated with or without dimethyl sulfoxide (DMSO, 1% final concentration). After 24 hours, medium with ALA (1 mmol/L final) was added for 4 hours. Cells were centrifuged and processed for reverse transcription PCR (RT-PCR), Western blot analysis, or PpIX analysis (spectrofluorimetry). For PpIX measurements, cell pellet were lysed in 1 mL Solvable (PerkinElmer) and centrifuged at 10,000 Â g at 4 C. PpIX content of 100 mL aliquots was measured in triplicate in 96-well plates (Corning) using a SpectraMAX Gemini-XS spectrofluorimeter (Molecular Devices) at 395 nm excitation and 635 nm emission wavelengths, respectively. PpIX levels were expressed as fluorescence units per mg of total protein. Protein concentrations of cell lysates were determined from absorbance at 280 nm rather than with Bradford reagent, which cross-reacts with Solvable.
Pretreatment of LNCaP cells with 1,25 dihydroxy vitamin D3 and PpIX analysis by confocal microscopy
LNCaP cells were plated on plastic cover slips in 35-mm dishes (50,000 cells/dish). At 24 hours, the medium was changed to fresh medium containing 10 À12 to 10 À6 mol/L 1,25 dihydroxy vitamin D3 (Vit D3) or vehicle (ethanol) alone. After 72 hours of incubation, medium containing 1 mmol/L ALA was added for 4 hours before PpIX analysis. PpIX-specific fluorescence in living cells was measured on a confocal laser-scanning microscope and digital images analyzed by image processing as described previously (8) . PpIX levels were expressed as arbitrary fluorescence units per cell.
C/EBP expression plasmid constructs, transient transfection of LNCaP cells, and PpIX analysis by confocal microscopy
Expression vectors for the C/EBP isoforms were as follows. Rat C/EBPa was cloned in pcDNA3.1, human C/EBPb1 (LAP Ã ) was cloned in pcDNA3.1/HisA, rat C/EBPb2 (LAP) was cloned in pcDNA3.1, rat C/EBPb3 (LIP) was cloned in pcDNA3.1, mouse C/EBPd was cloned in pcDNA3.1 and mouse C/EBPz/CHOP was cloned in pcDNA3.1. Expression vectors for C/EBPd and C/EBPb1 (LAP Ã ) were kindly provided by James Dewille (Ohio State University, Columbus, OH) and Linda Sealy (Vanderbilt University, Nashville, TN), respectively.
LNCaP cells were plated on 22 mm Â 22 mm, No. 1 plastic cover slips in a 35-mm dish (50,000 cells/dish). At 24 hours, cells were transiently transfected with C/EBP expression vectors (10 to 250 ng), or with pcDNA3.1 empty vector, using FuGENE 6 (Roche Diagnostics) as per the manufacturer's guidelines. At 24 hours posttransfection, fresh medium containing 1 mmol/L ALA was applied for 4 hours, then PpIX levels analyzed and quantified as described earlier.
Preparation of nuclear extracts
Nuclear extracts from COS-7 cells overexpressing individual C/EBP isoforms (a, b, d, and x) were prepared as described in ref. (28) . Expression of the C/EBP proteins in nuclear extracts was verified by Western blotting.
Western blot analysis
Western blot analyses were conducted as described previously (20, 25) . The source and dilution of antisera used were as follows: C/EBPa, C/EBPb, C/EBPd, CHOP, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH; Santa Cruz Biotechnology; 1:5,000); CPO (custom made, 1:5,000; ref. 5); horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin G (IgG; Jackson ImmunoResearch; 1:20,000).
Electrophoretic mobility shift assay
Complementary oligonucleotides ($43 nt) spanning either 1 or 2 C/EBP motifs from the murine CPO (mCPO) or human CPO (hCPO) promoters, along with corresponding mutated C/EBP motifs, were synthesized by Integrated DNA Technologies; sequences in Supplementary Table S1, part A. Duplex oligonucleotides were annealed, labeled with [a-32 P]dCTP, incubated with nuclear extracts, and the DNA-protein complexes resolved on polyacrylamide gels as described previously (25) . For supershift experiments, 1 mL of antibody was added to the incubation mixture for 15 minutes before addition of labeled oligonucleotides. For competition experiments, a 10 or 100 mol/L excess of unlabeled oligonucleotides was added to the mixture.
Luciferase reporter plasmid constructs and luciferase assay
Luciferase expression vector pSKLuc (25) containing mCPO promoter sequences (pSKLuc-946) was constructed by cloning a 946-bp fragment of the promoter (ref. 29 ; kind gift of Dr. Shigeru Taketani, Kyoto Institute of Technology, Japan) at NotI and XhoI sites. Three of the C/EBP motifs were mutated individually, using the sitespecific mutagenesis by overlap extension technique (30) . PCR-amplified products were cloned in pCRII-TOPO vector (Invitrogen) and sequenced to verify the mutation. Depending on their orientation in pCRII-TOPO, inserts carrying the C/EBP site mutations were cloned in pSKLuc vector as following: C7m at XhoI and KpnI; C6del, C6m, and C4m at SpeI and XhoI sites. See Supplementary Table S1, part B for details.
LNCaP cells were cultured in 6-well plates (100,000 cells/well) for 24 hours, then transfected with 1 mg of luciferase expression vectors (pSKLuc or pSKLuc-946) along with 10 to 250 ng of expression plasmid for various C/EBP isoforms (a, b, and d) and 1 mg of pSV-galactosidase expression plasmid (internal control), using FuGENE 6 (Roche Diagnostics) as per manufacturers guidelines. Cells were harvested 24 hours posttransfection; light output was measured using a luciferase assay kit (Promega) and normalized to the activity of b-galactosidase (b-Gal enzyme assay kit; Promega).
RT-PCR analyses
To detect semiquantitative changes in CPO mRNA levels in MEL cells, the following oligonucleotide (oligos) pairs were used. CPO: sense, 5
0 -AGGATGCTGTC-CATTTCCAC-3 0 ; CPO: antisense, 5 0 -GGGGAGTCA-AGATCGTCAAA-3 0 ; GAPDH: sense, 5 0 -ACCACAGTC-CATGCCATCAC-3 0 ; GAPDH: antisense, 5 0 -TCCACCA-CCCTGTTGCTGTA-3 0 (Integrated DNA Technologies DNA technology). RNA (2 mg) extracted from cells using TRIzol reagent (Invitrogen) were used for first-strand synthesis using gene-specific primers (antisense oligos for the genes mentioned earlier, 2 pmol/L each). The primers were used in reactions with SuperScript III Hreverse transcriptase (Invitrogen) as described by the manufacturer. For PCR, amplification, cycles were: 94 C 2 minutes, 94 C 45 seconds, 60 C 45 seconds, 72 C 45 seconds Â 25 to 28 cycles, and 72 C for 2 minutes. Amplification products were analyzed on 1.5% agarose gels along with size markers.
Scoring system for prediction of C/EBP binding at consensus sites in DNA
A comparative sequence approach was taken to identify features of the 17 candidate sites that might correlate with relative binding. In the Results subsection entitled "Nucleotide features of the C/EBP sites that are predictive of observed binding properties," the sequences were analyzed at the individual nucleotide (nt) level using a scoring system that we devised from the current literature on structural characteristics of optimized C/EBP:DNA complexes. Our scoring system combined available data from random site selection approaches (31, 32) and crystallographic studies (33) . C/EBP recognition sites are pseudo-palindromic sequences with a core half-site of GCAAT or very similar; an overall site of 10 bp comprises 2 abutted dyads, RTTGC * GYAAY, where R ¼ purines A or G, and Y ¼ pyrimidines C or T (32). In double-stranded DNA (dsDNA), at least 12 of 20 individual nt's in this 10-bp motif make contact with specific amino acids of the bound C/EBP protein, as shown in studies in which the binding domain of rat C/EBPa was crystallized with a DNA duplex containing the palindrome ATTGC * GCAAT (33). This structural information was used in our combined scoring system to define optimal nucleotides (NT's) at positions À4 to þ4. At positions À5 and þ5, for which crystallographic data were unavailable, PCR site-selection data (31, 32) were used to define the optimal nucleotides. In any given half-site, 7 key nucleotide locations (at þ1, þ2, þ3, and þ5 on the sense strand, and at À2, À3, and À4 on the antisense strand) were evaluated. A candidate C/EBP half-site whose nucleotides match the consensus at all locations would earn a score of 7 of 7.
Results
Differentiation therapy is associated with upregulation of C/EBPs, CPO gene expression, and PpIX production in tumors in vivo
We had previously shown that when subcutaneous A431 squamous tumors in mice (Fig. 1A) are preconditioned for 3 days with calcitriol (Vit D) and then given ALA for 4 hours, the PpIX photosensitizer accumulates to higher levels than in the absence of Vit D, causing more tumor cell death upon exposure to light (10) . After Vit D preconditioning and ALA (but before illumination), the histologic appearance of tumors seemed unaltered (Fig.  1B, left) . By immunostaining, however, levels of E-cadherin (a marker of differentiation; Fig. 1B , middle) and prominent expression of nuclear C/EBPb (Fig. 1B, right) were observed in the Vit D pretreated tumors. As noted previously, Vit D led to strong accumulation of PpIX (Fig.  1C) . Under these same conditions, relative levels of CPO protein were induced 4-to 5-fold ( Fig. 1D and E) , and C/ EBPb isoforms LIP, LAP, and LAP Ã were also increased ( Fig. 1D and E) . Semiquantitative analysis for each of the above molecular targets revealed 3-to 5-fold relative inductions for all (Fig. 1E) , supporting the hypothesis that elevated C/EBPb levels may drive CPO transcription and PpIX synthesis after vitamin D exposure.
Differentiating agents cause concurrent upregulation of C/EBP transcription factors and CPO gene transcription in vitro
To ask whether upregulation of CPO expression during the differentiation-enhanced PDT regimen might be mediated by C/EBP transcription factors, we turned to cell studies in vitro. Murine erythroleukemia cells (MEL), a well-established line for studying CPO expression, were tried initially. When MEL are incubated in 1% DMSO, large amounts of porphyrins are produced (34) and under these conditions C/EBPb expression is upregulated ( Fig.  2A, left) . Concurrently, CPO expression is increased at both mRNA and protein levels ( Fig. 2A, middle) , and higher levels of PpIX are generated in response to exogenously added ALA ( Fig. 2A, right) .
Because our previous studies on PDT were conducted in cells of epithelial origin (6), LNCaP (a human prostate carcinoma cell line) was chosen for further experiments (5, 7). When LNCaP were exposed to methotrexate, androgen, or calcitriol, C/EBPd protein levels increased after each of the 3 differentiation-promoting agents, and most dramatically after calcitriol (Fig. 2B) . C/EBPb levels were not significantly affected (data not shown). Calcitriolmediated induction of C/EBPd has been reported before (27) , but our goal was to ask whether increased C/EBPd is functionally associated with CPO induction and PpIX accumulation. Other carcinoma lines respond to calcitriol with increases in CPO and PpIX levels concurrently (9, 10) , and LNCaP cells proved to be no exception. PpIX inductions were observed even at very low effective concentrations of Vit D (pmol/L to nmol/L; see Fig. 2C ). Forcible overexpression of C/EBPd (and to lesser extent, C/EBPb) in LNCaP cells triggered PpIX accumulation, providing further evidence for a link between C/EBPs and the heme pathway ( Fig. 2D and E) .
The murine CPO gene upstream region contains many competent C/EBP-binding sites We now asked whether C/EBP factors can regulate CPO transcription by binding to DNA elements in the mCPO promoter/enhancer region. When our studies began, the mouse CPO gene had been cloned but little was known about its regulation (29, 35) . Using patternrecognition software (36) , 946 bp of mCPO upstream sequence were analyzed; 2 repeated clusters of sites were identified containing nt motifs highly homologous to the presumed C/EBP binding consensus (31, 37) . These candidate sites were named (ABCD) and (A'B'C'D'); see Fig.  3A . To test C/EBP binding, electrophoretic mobility shift assay (EMSA) was conducted using nuclear extracts from COS-7 cells overexpressing each of the major C/EBP isoforms, confirmed by Western blot analyses (Fig. 3B) . The relative ability of each site to bind C/EBPs was determined, as a function of DNA sequence and as a function of C/EBP isoform. First, the ability of one C/ EBP isoform to bind each DNA motif was tested. Nuclear extracts containing C/EBPb(LAP) were incubated with a 32 P-labeled dsDNA probe harboring one candidate motif, site A' (later renamed C6; Fig. 3C ). C/EBPb (LAP) bound to A', forming a specific protein-DNA complex (lane 2, shift) that was recognized by an anti-C/EBPb antibody (lane 3, supershift). Mutation of site A' abolished C/EBPb binding (lane 4). In this instance, another potential site (B') was located only 16 nucleotides away from A' in the mCPO promoter, so the dsDNA probe used in Fig. 3C contained both sites (probe A 0 -B'). To ask whether site A' or site B' contributed more to the observed binding, probes were created in which A' or B' was disrupted by mutation. C/EBPb(LAP) bound preferentially to site A' and not site B' (Fig. 3C, lane 5 vs. 4) .
We next asked whether site A 0 can bind other C/EBP isoforms. C/EBPa, C/EBPb(LIP), C/EBPb(LAP), C/ EBPb(LAP Ã ), and C/EBPd were shown to bind specifically to site A 0 , as shown by supershift experiments (Fig. 3D ). C/EBPz(CHOP) failed to bind (data not shown), an expected result as CHOP has an atypical bZIP region and does not bind conventional C/EBP consensus sites (38) . CHOP was not examined further here. C/EBP consensus sites have been historically difficult to recognize and define, due to sequence degeneracy and overlap with other transcription factor recognition sites (31, 32, 39) . Computer models could miss unconventional sites; a safer approach was to use a looser definition of nucleotides for consensus binding, and test a broad array of candidate sites experimentally. All potential motifs containing "GCAA," "CCAA," "ACAA," or "GTAA" were visually identified in a survey of 1,300 bp of mCPO promoter now available on http://www.ncbi.nlm.nih. gov; 17 candidate sites were identified (Fig. 3A) . To test the binding ability of each site, dsDNA probes ($40 bp, containing different consensus sites but identical flanking regions) were allowed to bind recombinant C/EBP proteins under identical reaction conditions. For example, Fig. 3E shows EMSA analyses in which C/ EBPb(LIP), or C/EBPd, were tested for binding at each of 17 sites. Each transcription factor bound very strongly to 3 sites (C6, C7, and C8), but bound differentially elsewhere; C/EBPb(LIP) formed prominent complexes at most sites, whereas C/EBPd bound more weakly (Fig. 3E) . Similar experiments for all C/EBP isoforms are summarized in Table 1 . Candidate consensus sites in Table 1 were classifiable into 4 groups: strong (3 sites), moderate (6 sites), weak (6 sites), and nonbinding (2 sites). Three strong sites (C6, C7, and C8) accounted for approximately 75% of relative binding overall. However, the 25% contribution from moderate and weak sites might also be important. To be sure that the relative affinity data in Table 1 are functionally relevant, we asked whether they can successfully predict a rank order of binding when sites are tested in competitive binding assays (Fig. 3F) . Three binding probes (sites C6, C3, and C10) with decreasing affinity (S, M, and W, respectively) were chosen for competition analyses (Fig. 3F) . For example, cross-competition experiments in panel B showed that C/EBPb binding to a moderate-affinity 32 P-labeled probe (M) is reduced by coincubation with a 10-fold excess of unlabeled S or M competitor probe, but not with the weakest (W) probe. In other panels of Fig. 3F , displacement of binding occurred as expected, relative to the predicted affinity.
Nucleotide features of the C/EBP sites that are predictive of observed binding properties
A comparative sequence analysis of the 17 candidate sites was undertaken to identify nt features that might correlate with relative binding. Details of the scoring system used in Fig. 4 are described in Materials and Methods and in the figure legend itself. Briefly, the scoring scheme generates a consensus score, based on published sequence-selection data (31, 32) and crystallographic studies (33) that indicate the optimal nt expected at any given location within each half-site of the C/EBP binding motif. This consensus score (the numerical value shown beneath each half-site in Fig. 4) indicates the "goodness of fit" to the data of Miller and colleagues (33) ; note that 7 of 7 indicate a perfect match. Examination of Fig. 4 suggests Figure 3 . Characterization of putative C/EBP binding sites in the mCPO promoter, by EMSA. A, schematic locations of the 17 candidate sites (see Fig. 5A for exact locations). B, Western blot analyses to verify proper expression of C/EBP isoforms. COS-7 cells were transfected with expression vectors encoding each of the C/EBP isoforms indicated, then analyzed on Western blot analyses using specific antisera. A 10-kDa molecular weight ladder was run in parallel, to establish the relative sizes of the visualized bands (kDa, on left). For the 3 C/EBPb isoforms (LIP, LAP, and LAP Ã ), which are translated from alternative translation start sites, a single antibody to the C-terminal end of C/EBPb was used. C, demonstration of specific binding at site A 0 . Nuclear extracts containing C/EBPb were incubated with the 32 P-labeled dsDNA probe indicated above each lane. Each probe contained 2 candidate sites (A 0 and B 0 ), located 16 bp apart. For probe Am 0 -B 0 or A 0 -Bm 0 , the sites A 0 or B 0 (respectively) were disrupted by mutation. NS, nonspecific bands. D, binding of different C/EBP isoforms to site A 0 . The test probe, A 0 -B 0 , was incubated with nuclear extracts overexpressing different C/EBP isoforms. Antibodies to C/EBPa, C/EBPb, or C/EBPd were added in some of the binding reactions to show specificity of the DNA-protein complexes (supershifts). E, EMSA to test the relative binding of C/EBP isoforms to candidate sites in the mCPO gene. EMSA was conducted with dsDNA probes representing each of the 17 candidate sites. In the figure, specific DNA-protein complexes formed with C/EBPb-LIP (top), or with C/EBPd (bottom), are illustrated. The results of experiments with all of the C/EBP isoforms are summarized in Table 1 . F, cross-competition analysis to test a predicted hierarchy of binding affinities. Three binding probes with relative affinities of 40% (site C6), 6% (site C3), and 3% (site C10) were chosen and for simplicity renamed strong (S), medium (M), and weak (W), respectively. Binding of C/EBPb-LAP to these that certain features of the consensus sequence may correlate with the hierarchy of relative C/EBP binding strength that was determined in Table 1 , but the relationships are not simple. Broadly speaking, each half-site to the right of the dyad axis of symmetry (as displayed in Fig.  4 ) determines the overall eligibility of the site to bind C/ EBPs, whereas the left half-site determines the ultimate strength of binding. In support of this statement, one can see that all bona fide C/EBP binding sites have similar consensus scores for the right half-site. A value of at least 5/7 for strong or moderate sites, and 4/7 for weak sites. Thus, a right-hand consensus score of 5/7 or higher is necessary but not sufficient for moderate-to-strong binding. To test this notion, we applied our scoring system to 25 additional gene promoters taken from the literature, each of which contained a proven C/EBP binding site, and in all but 2 cases the best half-site score was 5/7 or greater ( Supplementary Fig. S1 ).
If the right half-site determines binding eligibility, then the role of the left half-site may be to determine strong versus moderate versus weak affinity through the presence (or absence) of certain nucleotides that are unfavorable or inhibitory for binding. In moderate binding sites, a pyrimidine-to-pyrimidine substitution (C instead of T) is tolerated at position À4 (Fig. 4, red font) , although C is clearly less effective than the optimal T. For weak binding sequences, substitution of a relatively bulky purine (A or G) at position À4 for the optimal pyrimidine (T) is commonly observed (Fig. 4, red boxes) and seems to be inhibitory. Such pyrimidine-to-purine substitutions are highly unfavorable not only at position À4, but also at position þ2 (Fig. 4, purple boxes) . These substitutions are never observed in any of the C/EBP sites from the literature, which we assume to be strong or moderate-affinity sites (Supplementary Fig. S1 ). Interestingly, all C/EBP sites in mCPO are asymmetric, with wide divergence Isoform binding score: number of C/EBP isoforms that showed detectable binding to that particular DNA sequence. e Binding strength category of the nucleotide sequence, defined as follows: Strong, mean binding affinity is more than 10%; the site can bind to all 5 C/EBP isoforms. Moderate, mean binding affinity is at least 2%; the site can bind to 4 or more isoforms. Weak, mean binding affinity is less than 2%; the site can bind to at least 2 isoforms. Nonbinding, the site fails to bind to any of the C/EBP isoforms.
between the 2 half-sites (a substantial departure from a perfect palindrome; for example, site C-6). Asymmetry is also true for C/EBP sites in our literature survey, with rare exceptions; perfect symmetry was found only in the murine leptin and Ob promoters (Supplementary Fig. S1 ).
The arrangement of C/EBP sites in the upstream regions of mouse and human CPO favor cooperative transcriptional regulation
Fifteen functional C/EBP binding motifs in the mCPO promoter ( Fig. 5A and Table 1 ) is a substantial number, among the largest reported for any gene. To assess whether abundant C/EBP sites are unique to mCPO, we analyzed a similar length of the human CPO upstream region ($1.3 kb). C/EBP sites were identified by inspection, and binding was tested for a subset of these ( Supplementary  Fig. S2 and Fig. 5B ). Eighteen sites were identified in hCPO; all were predicted to bind C/EBPs with moderate or higher affinity based on the criteria in Fig. 4 . Five sites were randomly selected for EMSA, and shown to bind with strong-to-moderate affinity ( Supplementary Fig. S2 ). Overall, the number and arrangement of C/EBP sites in CPO genes from both species seems to be remarkably similar ( Fig. 5A and B) .
One might predict that strong-affinity sites are functionally more important than weaker sites for regulating transcriptional activation of the full-length mCPO promoter. Alternatively, moderate and weak sites might play a larger than anticipated role because they occur at regular spatial intervals along the mCPO sequence. To distinguish between these possibilities, 3 C/EBP sites with different binding strengths (strong, moderate, or weak) were randomly chosen for mutagenesis experiments. A full-length promoter-reporter construct, comprising 946 bp of intact, wild-type mCPO upstream sequence linked to a luciferase reporter, showed robust transcriptional activity and was induced by C/EBPb cotransfection as expected (Fig. 5C) . However, when C/EBP site-specific mutations were introduced into promoter-reporter constructs, all constructs showed similarly reduced expression, independent of the inherent binding affinities of individual sites (Fig. 5C ). These results were not due to technical issues; all constructs were verified by DNA sequencing. Rather, loss of inducibility due to the promoter mutations occurred reproducibly with all C/EBP isoforms (Supplementary Table S2 ), arguing that CPO promoter activity depends upon C/EBP site location, and not simply upon inherent binding affinity. A hypothetical model (Fig. 5D ) to support and interpret these findings is presented in the Discussion.
Discussion
Differentiation-enhanced PDT (DT/PDT) is a new cancer treatment concept (6) in which cellular differentiation accompanies an increase in expression of CPO, a major enzyme for protoporphyrin accumulation. This report establishes C/EBP transcription factors as a mechanistic link between enhanced differentiation and increased CPO expression in cancer cells. In several models, exposure to differentiation-promoting agents stimulates expression of C/EBPs, CPO mRNA, CPO protein, and PpIX. Direct, vector-based overexpression of C/EBPs also stimulates this pathway. A comprehensive examination of mouse and human CPO upstream gene regions revealed an astonishing number of C/EBP binding motifs (15 sites for mCPO, 18 for hCPO), each capable of binding major C/ EBP isoforms with high specificity. Tested in isolation, each DNA site showed a characteristic binding affinity (strong, moderate, or weak), but in the context of a fully intact promoter, mutational inactivation of individual sites (regardless of affinity) completely abolished C/ EBP-mediated transactivation. These findings, together with the remarkable regularity of C/EBP site spacing (suggesting the importance of site location), suggests that these sites regulate transcription in a cooperative fashion.
Cooperative interactions between multiple C/EBP recognition sites have been described before. For example, the keratin K10 and elafin gene promoters each contain 3 C/EBP sites that are all required for optimal promoter activity (25, 40) . Interestingly, 2 to 3 C/EBP sites are typically reported for many target genes (see Supplementary Fig. S1 ). In this regard, the 3 strongest C/EBP sites identified in the mCPO gene (C-6, C-7, and C-8) seem consistent with previous reports. What is novel here is the discovery of many additional medium-and low-affinity C/EBP sites in CPO genes that play a role in transcriptional regulation.
Evidence for a high degree of cooperativity, together with a similar distribution of C/EBP binding sites and related transcription factor sites in mouse and human CPO genes ( Fig. 5A and B) , led us to interpret our data within the framework of a transcriptional "enhanceosome." Enhancers are cis-acting DNA regulatory elements that control transcription, whereas enhanceosomes are higher-order complexes of enhancers and transcription factors assembled together on DNA, functioning together to modify local chromatin architecture and recruit the RNA polymerase machinery to the promoter (41). CPO upstream gene sequences display several key features required for an enhanceosome (42) . First, precise spacing between binding sites enables all protein components in the enhanceosome to contact each other and/or to contact the DNA, conferring great stability to the final complex. Consequently, deletion or mutation of a single binding site is often sufficient to inactivate the entire complex, as shown here. A second key feature is a dependence upon high-mobility group proteins, that is, "architectural" factors such as HMG I(Y) that bind to AT-rich sequences and facilitate DNA bending (43) . Interestingly, AT-rich sequences are present at approximately À1000 bp in both the mouse and human CPO genes. Third, enhanceosomes involve the participation of many classes of transcription factors simultaneously. All the factors highlighted in Fig. 5 (not only C/EBPs but also NF-kB, Sp1, AP-1, and CREB) are known to be expressed in LNCaP cells (44, 45) , and all of them can undergo protein-protein bridging interactions with coactivators (CBP/p300) and HMG proteins, as determined in studies with IL-6 (46) or the insulin receptor gene (47) . In our study of the CPO gene, only the C/EBP consensus sites were actually tested by EMSA (as opposed to identification by DNA sequence homology). However, this still allows us to make the point that in many genes, C/EBP sites have now been reported to lie in close Figure 4 . Comparative sequence analysis of C/EBP sites in the mCPO upstream region. Each dsDNA site for C/EBP binding consists of two 5-bp half-sites centered on a dyad axis of symmetry (vertical double lines). Boxes are shaded as follows: light green, this nt is identical to the nt shown to contact specific amino acids of C/EBP in the crystallographic studies of Miller and colleagues (33) . Yellow, deviations from the nt shown in Miller and colleagues. Dark green, a pyrimidine is the nt that occurs most commonly at position (þ5) in natural promoters (31, 32) . Red, purine at position À4 is sterically unfavorabe. Purple, a guanine is normally never observed at position þ2, except in weak or nonbinding sites. Gray, the nt at this location is not critical for binding (33) , and therefore not considered in the scoring system. Arrow, this nucleotide (þ1) defines the location of the site in the mCPO promoter. Numerals beneath each 5-bp half-site: this is the consensus score, that is, the number of nt's that match the theoretically perfect consensus sequence; 7 of possible 7 is perfect.
proximity to AP-1, NF-kB, and the other binding motifs of Fig. 5 (40, 48) . C/EBPs can heterodimerize not only with themselves, but also with other basic leucine-zipper transcription factors, including C/ATF and NF-kB, when binding at composite recognition elements (49, 50) . This raises the possibility that some of the moderate or weak Table 1 ) shown beneath. Mutated sequences are found in Supplementary Table S1 . D, hypothetical model of promoter-enhancer system (enhanceosome) regulating CPO transcription; see text for details.
sites identified here may in fact be composite elements. Growing evidence indicates that "every piece of real estate" on mammalian gene promoters is occupied by binding proteins, as shown for the IFN-b enhanceosome (42) . Such apparent complexity of molecular interactions offers opportunities for finely tuned combinations of transcription factors (differentially activated via receptor signaling pathways) to coordinately regulate CPO gene transcription.
In conclusion, these results support a new therapeutic platform that involves C/EBP-mediated cellular differentiation for a combination treatment of cancer. Further work is justified to fully explore the breadth and variety of cancers that may benefit from this approach.
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